InvestorsObserver
×
News Home

What is the Market's View on Akero Therapeutics Inc (AKRO) Stock's Price and Volume Trends Wednesday?

Wednesday, November 01, 2023 11:38 AM | InvestorsObserver Analysts

Mentioned in this article

What is the Market's View on Akero Therapeutics Inc (AKRO) Stock's Price and Volume Trends Wednesday?

Akero Therapeutics Inc (AKRO) stock has gained 6.31% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Akero Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AKRO!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With AKRO Stock Today?

Akero Therapeutics Inc (AKRO) stock is trading at $12.63 as of 11:26 AM on Wednesday, Nov 1, a rise of $0.70, or 5.91% from the previous closing price of $11.92. The stock has traded between $11.92 and $12.65 so far today. Volume today is light. So far 338,771 shares have traded compared to average volume of 2,724,515 shares. To see InvestorsObserver's Sentiment Score for Akero Therapeutics Inc click here.

More About Akero Therapeutics Inc

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis. Click Here to get the full Stock Report for Akero Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App